Immunotherapy in Renal Diseases

Medical Clinics of North America

Volumn 96, Issue 3, 2012, Pages 545-564

  Kher, Ajay ^a   Kher, Vijay ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MEDANTA THE MEDICITY   (India)

Author keywords

Crescentic glomerulonephritis; Glomerulonephritis; Immunosuppression; Nephrotic syndrome

Indexed keywords

ADALIMUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BELIMUMAB; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; FRESOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; MEPREDNISONE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPASE A2 RECEPTOR; PREDNISONE; RITUXIMAB; TACROLIMUS;

ANCA ASSOCIATED VASCULITIS; CHRONIC GLOMERULONEPHRITIS; CORTICOSTEROID THERAPY; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY BIOPSY; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MICROSCOPIC POLYANGIITIS; NEPHRITIS; NEPHROTIC SYNDROME; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PLASMAPHERESIS; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; METHOTREXATE; PLASMAPHERESIS; PROGNOSIS; RECURRENCE;

EID: 84862313931     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.04.007     Document Type: Review

References (131)

1. Marfo K., Lu A., Ling M., et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011, 6(4):922-936.
2. Webber A., Hirose R., Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation 2011, 91(10):1057-1064.
3. Rosenblatt J., McDermott D.F. Immunotherapy for renal cell carcinoma. Hematol Oncol Clin North Am 2011, 25(4):793-812.
4. Praga M., Gonzalez E. Acute interstitial nephritis. Kidney Int 2010, 77(11):956-961.
5. Abboud H., Henrich W.L. Clinical practice. Stage IV chronic kidney disease. N Engl J Med 2010, 362(1):56-65.
6. Tune B.M., Mendoza S.A. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997, 8(5):824-832.
7. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981, 98(4):561-564.
8. Black D.A., Rose G., Brewer D.B. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J 1970, 3(5720):421-426.
9. Coggins C.H. Adult minimal change nephropathy: experience of the collaborative study of glomerular disease. Trans Am Clin Climatol Assoc 1986, 97:18-26.
10. Imbasciati E., Gusmano R., Edefonti A., et al. Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. Br Med J (Clin Res Ed) 1985, 291(6505):1305-1308.
11. Nakayama M., Katafuchi R., Yanase T., et al. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002, 39(3):503-512.
12. Tse K.C., Lam M.F., Yip P.S., et al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol Dial Transplant 2003, 18(7):1316-1320.
13. Nolasco F., Cameron J.S., Heywood E.F., et al. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int 1986, 29(6):1215-1223.
14. Fujimoto S., Yamamoto Y., Hisanaga S., et al. Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis 1991, 17(6):687-692.
15. Mak S.K., Short C.D., Mallick N.P. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant 1996, 11(11):2192-2201.
16. Gulati S., Kher V., Sharma R.K., et al. Steroid response pattern in Indian children with nephrotic syndrome. Acta Paediatr 1994, 83(5):530-533.
17. Tarshish P., Tobin J.N., Bernstein J., et al. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997, 8(5):769-776.
18. Cattran D.C., Alexopoulos E., Heering P., et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007, 72(12):1429-1447.
19. Meyrier A., Condamin M.C., Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 1991, 35(Suppl 1):S37-S42.
20. Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol Dial Transplant 2003, 18(Suppl 6):vi79-vi86.
21. Bargman J.M. Management of minimal lesion glomerulonephritis: evidence-based recommendations. Kidney Int Suppl 1999, 70:S3-S16.
22. Waldman M., Crew R.J., Valeri A., et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007, 2(3):445-453.
23. Ponticelli C., Rizzoni G., Edefonti A., et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993, 43(6):1377-1384.
24. Elhence R., Gulati S., Kher V., et al. Intravenous pulse cyclophosphamide-a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol 1994, 8(1):1-3.
25. Glassock R.J. Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003, 23(4):324-332.
26. Schieppati A., Mosconi L., Perna A., et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993, 329(2):85-89.
27. Hall C.L., Fothergill N.J., Blackwell M.M., et al. The natural course of gold nephropathy: long term study of 21 patients. Br Med J (Clin Res Ed) 1987, 295(6601):745-748.
28. Hall C.L., Jawad S., Harrison P.R., et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988, 296(6629):1083-1086.
29. Pei Y., Cattran D., Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992, 42(4):960-966.
30. Cattran D.C., Pei Y., Greenwood C.M., et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997, 51(3):901-907.
31. Jha V., Ganguli A., Saha T.K., et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007, 18(6):1899-1904.
32. Ponticelli C., Zucchelli P., Passerini P., et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995, 48(5):1600-1604.
33. Ponticelli C., Altieri P., Scolari F., et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998, 9(3):444-450.
34. Cattran D.C., Appel G.B., Hebert L.A., et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001, 59(4):1484-1490.
35. Alexopoulos E., Papagianni A., Tsamelashvili M., et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 2006, 21(11):3127-3132.
36. Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005, 16(5):1188-1194.
37. Fervenza F.C., Abraham R.S., Erickson S.B., et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010, 5(12):2188-2198.
38. Fervenza F.C., Cosio F.G., Erickson S.B., et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008, 73(1):117-125.
39. Beck L.H., Bonegio R.G., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361(1):11-21.
40. Hofstra J.M., Beck L.H., Beck D.M., et al. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011, 6(6):1286-1291.
41. Beck L.H., Fervenza F.C., Beck D.M., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011, 22(8):1543-1550.
42. Rydel J.J., Korbet S.M., Borok R.Z., et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995, 25(4):534-542.
43. Korbet S.M., Schwartz M.M., Lewis E.J. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994, 23(6):773-783.
44. Wehrmann M., Bohle A., Held H., et al. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990, 33(3):115-122.
45. Korbet S.M. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 1998, 9(7):1333-1340.
46. Troyanov S., Wall C.A., Miller J.A., et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005, 16(4):1061-1068.
47. Banfi G., Moriggi M., Sabadini E., et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991, 36(2):53-59.
48. Cattran D.C., Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998, 32(1):72-79.
49. Chun M.J., Korbet S.M., Schwartz M.M., et al. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004, 15(8):2169-2177.
50. Ponticelli C., Villa M., Banfi G., et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?. Am J Kidney Dis 1999, 34(4):618-625.
51. Cattran D.C., Appel G.B., Hebert L.A., et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999, 56(6):2220-2226.
52. Heering P., Braun N., Mullejans R., et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004, 43(1):10-18.
53. Cattran D.C., Wang M.M., Appel G., et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004, 62(6):405-411.
54. Gipson D.S., Trachtman H., Kaskel F.J., et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011, 80(8):868-878.
55. Austin H.A., Klippel J.H., Balow J.E., et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986, 314(10):614-619.
56. Boumpas D.T., Austin H.A., Vaughn E.M., et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992, 340(8822):741-745.
57. Gourley M.F., Austin H.A., Scott D., et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996, 125(7):549-557.
58. Illei G.G., Austin H.A., Crane M., et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001, 135(4):248-257.
59. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010, 69(1):61-64.
60. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004, 50(12):3934-3940.
61. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46(8):2121-2131.
62. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004, 350(10):971-980.
63. Appel G.B., Contreras G., Dooley M.A., et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20(5):1103-1112.
64. Isenberg D., Appel G.B., Contreras G., et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010, 49(1):128-140.
65. Dooley M.A., Hogan S., Jennette C., et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997, 51(4):1188-1195.
66. Chan T.M., Tse K.C., Tang C.S., et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005, 16(4):1076-1084.
67. Chan T.M., Li F.K., Tang C.S., et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000, 343(16):1156-1162.
68. Walsh M., James M., Jayne D., et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007, 2(5):968-975.
69. Ioannidis J.P., Boki K.A., Katsorida M.E., et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000, 57(1):258-264.
70. Mosca M., Bencivelli W., Neri R., et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002, 61(4):1502-1509.
71. Moroni G., Gallelli B., Quaglini S., et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006, 21(6):1541-1548.
72. Grootscholten C., Berden J.H. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?. Nephrol Dial Transplant 2006, 21(6):1465-1469.
73. Houssiau F.A., D'Cruz D., Sangle S., et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 2010, 69(12):2083-2089.
74. Dooley M.A., Jayne D., Ginzler E.M., et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011, 365(20):1886-1895.
75. Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006, 8(3):R83.
76. Melander C., Sallee M., Trolliet P., et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009, 4(3):579-587.
77. Najafi C.C., Korbet S.M., Lewis E.J., et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001, 59(6):2156-2163.
78. Bao H., Liu Z.H., Xie H.L., et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008, 19(10):2001-2010.
79. Donadio J.V., Grande J.P. IgA nephropathy. N Engl J Med 2002, 347(10):738-748.
80. Alamartine E., Sabatier J.C., Guerin C., et al. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991, 18(1):12-19.
81. 51Cr-EDTA clearance. Kidney Int 1991, 40(6):1050-1054.
82. Geddes C.C., Rauta V., Gronhagen-Riska C., et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 2003, 18(8):1541-1548.
83. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000, 36(2):227-237.
84. Wakai K., Kawamura T., Endoh M., et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 2006, 21(10):2800-2808.
85. Reich H.N., Troyanov S., Scholey J.W., et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007, 18(12):3177-3183.
86. Berthoux F., Mohey H., Laurent B., et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011, 22(4):752-761.
87. El Karoui K., Hill G.S., Karras A., et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int 2011, 79(6):643-654.
88. Herzenberg A.M., Fogo A.B., Reich H.N., et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011, 80(3):310-317.
89. Shi S.F., Wang S.X., Jiang L., et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol 2011, 6(9):2175-2184.
90. Appel G.B., Waldman M. The IgA nephropathy treatment dilemma. Kidney Int 2006, 69(11):1939-1944.
91. Barratt J., Feehally J. Treatment of IgA nephropathy. Kidney Int 2006, 69(11):1934-1938.
92. Nolin L., Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl 1999, 70:S56-S62.
93. Pozzi C., Bolasco P.G., Fogazzi G.B., et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999, 353(9156):883-887.
94. Pozzi C., Andrulli S., Del Vecchio L., et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004, 15(1):157-163.
95. Katafuchi R., Ikeda K., Mizumasa T., et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003, 41(5):972-983.
96. Manno C., Torres D.D., Rossini M., et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009, 24(12):3694-3701.
97. Lv J., Zhang H., Chen Y., et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2009, 53(1):26-32.
98. Lai K.N., Lai F.M., Leung A.C., et al. Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: a report of two cases and review of literature. Am J Kidney Dis 1987, 10(1):66-70.
99. Roccatello D., Ferro M., Coppo R., et al. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant 1995, 10(11):2054-2059.
100. McIntyre C.W., Fluck R.J., Lambie S.H. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. Clin Nephrol 2001, 56(3):193-198.
101. Tumlin J.A., Lohavichan V., Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003, 18(7):1321-1329.
102. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116(6):488-498.
103. Nachman P.H., Hogan S.L., Jennette J.C., et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7(1):33-39.
104. de Groot K., Adu D., Savage C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001, 16(10):2018-2027.
105. de Groot K., Harper L., Jayne D.R., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009, 150(10):670-680.
106. Guillevin L., Cordier J.F., Lhote F., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997, 40(12):2187-2198.
107. Haubitz M., Schellong S., Gobel U., et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998, 41(10):1835-1844.
108. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352(4):351-361.
109. Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349(1):36-44.
110. Jones R.B., Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363(3):211-220.
111. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232.
112. Pusey C.D., Rees A.J., Evans D.J., et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991, 40(4):757-763.
113. Jayne D.R., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18(7):2180-2188.
114. Klemmer P.J., Chalermskulrat W., Reif M.S., et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003, 42(6):1149-1153.
115. Langford C.A., Talar-Williams C., Barron K.S., et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003, 114(6):463-469.
116. Pagnoux C., Mahr A., Hamidou M.A., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008, 359(26):2790-2803.
117. Hiemstra T.F., Walsh M., Mahr A., et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010, 304(21):2381-2388.
118. Wilson C.B., Dixon F.J. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973, 3(2):74-89.
119. Pusey C.D. Anti-glomerular basement membrane disease. Kidney Int 2003, 64(4):1535-1550.
120. Levy J.B., Turner A.N., Rees A.J., et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001, 134(11):1033-1042.
121. Savage C.O., Pusey C.D., Bowman C., et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986, 292(6516):301-304.
122. Madore F., Lazarus J.M., Brady H.R. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996, 7(3):367-386.
123. Jindal K.K. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl 1999, 70:S33-S40.
124. Johnson J.P., Moore J., Austin H.A., et al. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985, 64(4):219-227.
125. Bagga A., Sinha A., Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007, 356(26):2751-2752.
126. Fujinaga S., Hirano D., Nishizaki N., et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010, 25(3):539-544.
127. Guigonis V., Dallocchio A., Baudouin V., et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008, 23(8):1269-1279.
128. Haffner D., Fischer D.C. Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 2009, 24(8):1433-1438.
129. Navarra S.V., Guzman R.M., Gallacher A.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377(9767):721-731.
130. Trachtman H., Vento S., Gipson D., et al. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol 2011, 12:8.
131. Trachtman H., Fervenza F.C., Gipson D.S., et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011, 79(11):1236-1243.